Efficacy of golimumab in children with polyarticular juvenile idi-opathic arthritis

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


Golimumab is a human anti- monoclonal antibody against tumor necrosis factor alpha (TNF-α) TNF-α is one of the main proinflammatory cytokines taking part in JRA’s (juvenile idiopathic arthritis) pathogenesis. To compare with currently used tumor necrosis factor inhibitors golimumab therapy has high compliance because of low pain in the site of injection and long half-life period. The efficacy of golimumab was demonstrated earlier in adults with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis. 10 children with active polyarticular JRA despite previous methotrexate treatment were enrolled in randomized study. All patients received subcutaneous golimumab 30 mg/kg every 4 weeks. At week 16 patients were randomly assigned to one of two treatment arms: 4 of them received placebo, others continued subcutaneous golimumab at the same dose. 3 of 4 children who received placebo later continued golimumab because of confirmed flare. Assessments were performed at week 24 and at the moment of last visit available for assessment (week 96-week 116) Dynamics of main clinical and laboratory disease activity measures were evaluated, including JA-DAS and CDAI dynamics and ACRPedi response criteria. During this study the majority of patients showed significant improvement of disease activity measures and their components with good ACR-Pedi response without serious adverse events and significant changes in blood count (erythrocytes, leukocytes and hemoglobin). According study results, golimumab can be evaluated as effective and quite safe therapy of polyarticular JRA.

Full Text

Restricted Access

About the authors

Ekaterina Mikhaylovna Kuchinskaya

Saint Petersburg State Pediatric Medical University

Email: kuchinskaya.link@gmail.com
MD, Research Fellow, Chair of Hospital Pediatrics

Mikhail Mikhaylovich Kostik

Saint Petersburg State Pediatric Medical University

Email: mikhail.kostik@gmail.com
Associate Professor, Chair of Hospital Pediatrics

Ludmila Stepanovna Snegireva

Saint Petersburg State Pediatric Medical University

Email: l.s.snegireva@mail.ru
MD, Department of Pediatrics N 3

Olga Valeryevna Kalashnikova

Saint Petersburg State Pediatric Medical University

Email: koira7@yandex.ru
MD, PhD, Associate Professor, Chair of Hospital Pediatrics

Margarita Fedorovna Dubko

Saint Petersburg State Pediatric Medical University

Email: andrq@rambler.ru
MD, PhD, Associate Professor, Chair of Hospital Pediatrics

Vera Vasil’yevna Masalova

Saint Petersburg State Pediatric Medical University

Email: masalova.vera@gmail.com
MD, Research Fellow, Chair of Hospital Pediatrics

Tatyana Serafimovna Likhacheva

Saint Petersburg State Pediatric Medical University

Email: tatianasl@list.ru
MD, Research Fellow, Chair of Hospital Pediatrics


  1. Alonso A., González C. M., Ballina J., García Vivar M. L., Gómez-Reino J. J., Marenco J. L., Fernández-Nebro A., Ordás C., Cea-Calvo L., Arteaga M. J., Sanmartí R. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: Results of the GO-MORE study in Spain. Reumatol Clin. 2014 July 9 Available from: http://www.reumatologiaclinica.org/en/linkresolver/eficacia-seguridad-golimumab-anadido-farmacos/S1699-258X (14)00122-3/.
  2. Chovel-Sella A., Karplus R., Sella T., Amital H. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis. Isr Med Assoc J. 2012 Jun; 14 (6): 390-4.
  3. Cordero-Coma M., Calvo-Río V., Adán A., Blanco R., Álvarez-Castro C., Mesquida M., Calleja S., González-Gay M. A., Ruíz de Morales J. G. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014; [cited 2014 May 28]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058145/.
  4. Lippert E., Müller M., Ott C. Golimumab in unresponsive ulcerative colitis. Biologics. 2014 May 27; 8: 207-10.
  5. Mandell B. F., Sobell J. M. The Role of TNF Inhibitors in Psoriatic Disease. Semin Cutan Med Surg. 2014 Jun 15; 33 (4s): 64-8.
  6. Mazumdar S., Greenwald D. Golimumab. MAbs. 2009 Sep-Oct; 1 (5): 422-31.
  7. Miserocchi E., Modorati G., Pontikaki I., Meroni P. L., Gerloni V. [4] Long-term treatment with golimumab for severe uveitis.Ocul Immunol Inflamm. 2014 Apr; 22 (2): 90-5.
  8. Oldfield V., Plosker G. L. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs. 2009; 23 (2): 125-35.
  9. Rodgers M., Epstein D., Bojke L., Yang H., Craig D., Fonseca T., Myers L., Bruce I., Chalmers R., Bujkiewicz S., Lai M., Cooper N., Abrams K., Spiegelhalter D., Sutton A., Sculpher M., Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011 Feb; 15 (10): 1-329.
  10. Walters H. M., Pan N., Lehman T. J., Adams A., Huang W. T., Sitaras L., Cunningham-Rundles S., Walsh T. J., Toussi S. S. A prospective study comparing infection risk and disease activity in children with juvenile idiopathicarthritis treated with and without tumor necrosis factor-alpha inhibitors. Clin Rheumatol. 2014 Sep 18. Available from: http://link.springer.com.sci-hub.org/article/10.1007/s10067-014-2779-8/fulltext.html.



Abstract - 1324

PDF (Russian) - 345


Article Metrics

Metrics Loading ...



Copyright (c) 2014 Kuchinskaya E.M., Kostik M.M., Snegireva L.S., Kalashnikova O.V., Dubko M.F., Masalova V.V., Likhacheva T.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies